Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 卫信康医药初创于2002年，正式成立于2006年，2013年更名为西藏卫信康医药股份有限公司，2017年于上交所主板上市（证券代码603676.SH）。卫信康现有13家分子公司，分布于北京、西藏、内蒙古、海南、江苏、香港、新加坡等地，员工近800人。 公司以临床需求为导向，立足于研发创新，坚持仿创结合，是一家集药品研发、生产、销售为一体的综合性高科技医药企业，在静脉维生素类、静脉微量元素类、静脉电解质类等领域具备显著优势。 公司作为成人及儿童肠外营养用药专家，主导产品包括注射用多种维生素（12）、小儿多种维生素注射液（13）、多种微量元素注射液、复方氨基酸注射液(20AA)、小儿复方氨基酸注射液(19AA-Ⅰ)、吸入用乙酰半胱氨酸溶液、注射用门冬氨酸钾镁、蔗糖铁注射液、复方电解质注射液（II）、复方电解质注射液（V）、混合糖电解质注射液等多种产品。 公司研发中心现有研发人员近200人，科研骨干药物研发经验平均10年以上，目前产品技术开发已形成“新型注射剂工艺技术平台”、“大复方制剂技术平台”、“新型冷冻干燥技术平台”三大技术平台，并向口服固体制剂研发平台、新型给药系统研发平台延伸。公司自主研发累计取得15项发明专利，自2015年以来取得17项新药证书，13个药品19个注册批件，40多个项目正在研发中，多个项目在注册审评审批中。公司建立了专业、高效的市场销售网络，商务体系已覆盖全国3000多家二级以上终端医疗机构，覆盖全国主流商业渠道和绝大部分省份，可为合作伙伴提供专业化、定制化的商业化解决方案。 公司始终秉承“以人为本，共求卓越”的人才理念，吸引了一大批专业人才的加盟，为公司的长远发展奠定了厚实的人才基础。未来，卫信康将继续坚持“关爱生命，维护健康”的企业使命，根植中国，面向世界，专注健康事业，聚焦前沿领域，进一步顺应医药产业发展趋势，持续提高创新能力及技术水平，提供更多创新性、可及的治疗方案，推动公司向现代化和规模化的高科技医药产业方向迈进，致力于成为受社会尊重的、领先的专业化仿创医药企业。
Main Business 化学药品制剂及其原料药的研发、生产、销售。
Legal Representative 张勇
Top Executives
董事长：张勇
董事：刘烽,陈仕恭,刘彬彬
独立董事：曹磊,许晓芳,赵艳萍
Top 5 Shareholder
Shareholder name Nature Holding Date
西藏卫信康企业管理有限公司流通A股47.17%31/03/2024
张勇流通A股12.27%31/03/2024
钟丽娟流通A股8.27%31/03/2024
天津京卫信康管理咨询合伙企业（有限合伙）流通A股7.75%31/03/2024
刘烽限售股+流通A股0.88%31/03/2024
Company Secretary 于海波
Solicitors 广东信达律师事务所
Auditors 北京国友大正资产评估有限公司;瑞华会计师事务所（特殊普通合伙）
Tel No 0891-6601760;010-50870100
Fax No 0891-6601760;010-50870100
Website www.wxkpharma.com
Email wxk@wxkpharma.com
Company Address
Register: 拉萨经济技术开发区B区园区南路5号工业中心4号楼3层
Office: 西藏自治区拉萨经济技术开发区B区园区南路5号工业中心4号楼3层
Listing Date 21/07/2017
Shares Capital
Shares Capital: 435,161,500
Total A Share: 435,161,500
Listed A Share: 429,102,000
Non-tradable A Share: 6,059,500
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.500
DPS(RMB)* ¥ 0.285
NBV Per Share(RMB)* ¥ 3.080
Market Capitalization(RMB) 4.055B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.